Intuitive Surgical Sinks 6% as U.S. da Vinci Growth Slows to “Lowest We’ve Seen Since COVID”
Intuitive Surgical (ISRG) shares dropped 6% after reporting Q3 revenue of $3.05B, adjusted EPS of $3.00, and U.S. da Vinci procedure growth of 10%, the lowest since COVID. The company narrowed its 2026 procedure growth outlook and took a $450M antitrust charge. Management plans to cut instrument and accessory revenue per procedure by 3%-5% to boost volume.
How this was made
The 30-second read
Why it matters
The earnings beat was eclipsed by the slowdown in a core growth driver, leading to a 6% share decline. Margin guidance remains strong, potentially cushioning the downside.
Market read
The earnings release introduces new guidance and a notable slowdown in U.S. procedure growth, directly affecting ISRG's stock price.
What to watch
The $450M antitrust settlement charge is non‑recurring and may be viewed as a one‑time hit.
Background
Intuitive Surgical (ISRG) released its third‑quarter earnings, beating revenue and EPS estimates but highlighted a slowdown in U.S. da Vinci procedure growth to its lowest level since COVID.
Ticker impact
Intuitive Surgical reported Q3 results with revenue and EPS beat but disclosed U.S. da Vinci procedure growth slowed to 10%, causing a 6% share drop.
likely downward pressure as investors price in slower U.S. procedure growth despite margin guidance.
The earnings beat is outweighed by the slowdown in a key growth metric and a $450M settlement charge, prompting a sell‑off.
Market effects
Robotic surgery equipment sector may see heightened scrutiny on growth assumptions.
U.S. healthcare investors could reassess exposure to surgical robotics.
Limited to Intuitive Surgical; no broad market impact.
Counterpoint
Margin expansion and lower valuation multiples could present a buying opportunity if volume rebounds.
Key entities
- CompanyIntuitive Surgical
Provider of da Vinci surgical robots.
- AnalystWells Fargo
Provided commentary on the earnings call.
